Advanced Hodgkin's lymphoma: End-of-treatment FDG-PET should be maintained

Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1254-1257. doi: 10.1007/s00259-017-3714-4.

Authors

Elif Hindié¹, Charles Mesguich², Krimo Bouabdallah³, Noël Milpied³

Affiliations

¹ Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France. elif.hindie@chu-bordeaux.fr.
² Department of Nuclear Medicine, Bordeaux University Hospital, Bordeaux, France.
³ Department of Hematological Oncology, Bordeaux University Hospital, Bordeaux, France.

PMID: 28466283
DOI: 10.1007/s00259-017-3714-4

No abstract available

Publication types

Editorial
Comment

MeSH terms

Fluorodeoxyglucose F18
Hodgkin Disease*
Humans
Lymphoma, Non-Hodgkin
Neoplasm Staging
Positron-Emission Tomography*
Radiopharmaceuticals

Substances

Radiopharmaceuticals
Fluorodeoxyglucose F18